# Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

> **NCT05266417** · PHASE2 · RECRUITING · sponsor: **Gateway Institute for Brain Research** · enrollment: 56 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** INS-GSH
- **DRUG:** Matched Placebos

## Key facts

- **NCT ID:** NCT05266417
- **Lead sponsor:** Gateway Institute for Brain Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-07
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-07-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266417, "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05266417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*